ÂÜÀòÂÒÂ×

Katja Hempel has a strong background in drug safety and toxicology. Katja is currently the Head of Nonclinical Drug Safety in Germany and Vice President at Boehringer Ingelheim. Katja'sresponsibilities include developing the nonclinical drug safety strategy within Development Sciences. Prior to this role, they worked at AbbVie as a Director, where they held various positions including Early Neuroscience Therapeutic Area Lead, Head of Scientific and Analytical Platform, and Senior Principal Safety Scientist. Katja also has experience at Abbott as an Associate Director in Toxicology. Earlier in their career, they worked at BASF as a Senior Scientist and Head of service and contract management team, where they were responsible for selecting appropriate CROs and ensuring compliance with animal welfare, GLP, and regulatory requirements. Katja also served as a Toxicologist and Head of Laboratory, overseeing toxicological studies for agrochemicals and pharmaceuticals.

Katja Hempel's education history includes a Senior Scientist position at BASF SE from an unknown start year to 2012. Katja also holds a degree as a Veterinary Specialist for Pharmacology and Toxicology from BASF SE, earned from 2001 to 2010. Prior to that, they obtained a Dr. med. vet degree in Veterinary Medicine from Ludwig-Maximilians-Universität München, attending from 1997 to 2000. Katja also completed a DVM degree in Veterinary Medicine from the same university, studied between 1994 and 1996. Additionally, they pursued Veterinary Medicine at Universidad Austral de Chile, Valdivia, for the 1993-1994 academic year, and studied Veterinary medicine at Ludwig-Maximilians-Universität München from 1990 to 1992.